BNIGF News and Press, Beroni Group Ltd

Sydney, Australia (ABN Newswire) - Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into an unsecured and interest free convertible loan agreement with a group of investors for a principal loan amount of US$410,397. The loan is convertible at US$1.00 per share (post-...

Sydney, Australia (ABN Newswire) - Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into an unsecured and interest free convertible loan agreement with an investor for a principal loan amount of US$205,679. The loan is convertible at US$1.00 per share upon listing of the...

Sydney, Australia (ABN Newswire) - Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into unsecured and interest free convertible loan agreements with two investors for an aggregate principal loan amount of US$291,545. The loan is convertible at US$1.50 per share upon...

Sydney, Australia (ABN Newswire) - Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, announced that its enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method has been undergoing clinical trial in China, for eventual application to the Nati...

NEW YORK and SYDNEY, June 01, 2022 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, announced that it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL...

Sydney, Australia (ABN Newswire) - Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, announced that it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its latest enhanced COVID-19 Antigen Ra...

NEW YORK and SYDNEY, Australia, March 31, 2022 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercializatio...

NEW YORK and SYDNEY, Australia, March 23, 2022 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercializatio...

Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio’s pipeline includes three bispecific antibodies in the IND and pre-IND stages, and a variety of early-stage antibodies and other biologics products. Swe...

NEW YORK and SYDNEY, Australia, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization...